503A Compounding Pharmacies: What They Are and How They Work
What healthcare organizations need to know about 503A compounding pharmacies, how they operate, and the standards they uphold.
For healthcare organizations offering customized medication programs, compounding pharmacies are a critical part of the clinical infrastructure. But the regulatory framework around them is often misunderstood. Here's what each designation actually means and what it requires.
Let’s walk through what 503A compounding pharmacies are, how they function, and what standards they operate under.
What Is Drug Compounding?
Drug compounding is the process of preparing a customized medication for an individual patient when a commercially available, FDA-approved drug is not suitable for their needs as determined by a licensed practitioner after establishing a valid patient-provider relationship.
Only properly licensed pharmacists or physicians may legally compound drugs for patients with specific medical needs — such as allergies, inability to swallow tablets or drug shortages.
Compounding combines or alters ingredients to create a customized medication, often in a different strength or dosage form.
Compounded drugs are not FDA-approved, meaning the FDA does not verify their safety, effectiveness, or quality before they are marketed. This is why the standards compounding pharmacies must follow, and how those pharmacies are regulated, matter significantly for patient safety.
What Is a 503A Compounding Pharmacy?
503A is shorthand for Section 503A of the Federal Food, Drug, and Cosmetic Act, the federal law that sets the rules for how traditional compounding pharmacies can operate outside of the standard FDA drug approval process.
To qualify under Section 503A, a compounding pharmacy must be:
A state-licensed pharmacy operating under the oversight of the state board of pharmacy where they operate as well as any other state boards of pharmacies where they ship medications
Compounding medications based on valid, patient-specific prescriptions from licensed providers
Using bulk drug substances that meet applicable standards, including sourcing from FDA-registered manufacturers with valid certificates of analysis
503A pharmacies are allowed to compound and dispense patient-specific, personalized medications based on valid prescriptions from licensed providers but cannot manufacture drugs in bulk for general distribution.
How Does 503A Compounding Work?
The 503A compounding process follows a defined clinical and operational pathway:
A licensed provider determines that a commercially available FDA-approved medication is not appropriate for a specific patient
The provider writes a valid prescription for a compounded medication tailored to that patient's specific needs
The prescription is sent to a licensed 503A compounding pharmacy, the licensed pharmacist reviews and, if appropriate, approves, compounds the medication according to the prescription
The patient-specific compounded medication is dispensed directly to the patient or their agent for home use
503A pharmacies can also prepare small quantities of a medication before receiving a prescription, as long as there is a documented history of orders for that product within an established prescriber-patient relationship. This is called anticipatory compounding and is subject to defined limitations.
503A pharmacies are not permitted to compound in bulk for office stock or general distribution to healthcare facilities. That pathway falls under 503B outsourcing facilities, which we will discuss below.
What Standards Do 503A Pharmacies Have to Meet?
503A compounding pharmacies operate under a layered compliance framework that includes both federal and state requirements.
Federal requirements
Bulk drug substances used in compounding must be manufactured by an FDA-registered establishment and accompanied by a valid certificate of analysis
Substances used must comply with all applicable United States Pharmacopeia (USP) or National Formulary (NF) monographs, or appear on the FDA's list of approved bulk drug substances
Pharmacies may not compound drugs that have been withdrawn from the market for safety reasons
Pharmacies may not compound essentially copies of commercially available drug products unless the drug is on the FDA’s drug shortage list at the time of compounding anddispensing.. Such copies are prohibited if made regularly or in inordinate amounts.
State requirements
503A pharmacies must be licensed by and comply with the state board of pharmacy where they operate as well as any other other state boards of pharmacies where they ship medications
Environmental monitoring must be performed every six months
Pharmacies must comply with USP Chapters 795 (nonsterile compounding), 797 (sterile compounding) and 800 (hazardous drugs) standards, which govern facility design, personnel training, quality testing, and strict Beyond Use Dating (BUD) for compounded preparations
Inspection and oversight
503A pharmacies are primarily regulated by state boards of pharmacy, not the FDA
FDA may conduct inspections in response to adverse event reports or quality complaints, but does not routinely inspect 503A facilities on a scheduled basis
Pharmacies are not required to register with FDA or report adverse events to the agency
In short, the burden of quality is shared. Both the pharmacy and the organizations that work with them need to hold the standard.
503A vs. 503B: What Is the Difference?
The Drug Quality and Security Act (DQSA) of 2013 created a second category of compounders: 503B outsourcing facilities. Understanding the distinction matters for healthcare organizations designing medication programs.
| 503A Compounding Pharmacy | 503B Outsourcing Facility |
Prescription requirement | Required — patient-specific | Not required — may compound without individual prescriptions |
Who it serves | Individual patients | Healthcare facilities, hospitals, providers for office stock |
CGMP requirements | Exempt | Required |
FDA registration | Not required | Required - annual registration |
FDA inspection schedule | For cause only | Risk-based scheduled inspections |
Adverse event | Not required | Required |
Scale | Custom, patient-specific prescriptions | Large-scale production permitted |
Sources: FDA.gov 503A | The FDA Group, 503A vs. 503B
For most telehealth and outpatient clinical programs, 503A pharmacies are the appropriate partner because the medication is being prescribed for an identified, individual patient rather than stocked for general use.
What This Means for Healthcare Organizations
For organizations that include compounded medications in their clinical programs, choosing the right pharmacy partner is an operational and compliance decision, not just a sourcing one.
Key considerations when working with a 503A pharmacy:
Valid prescriptions are non-negotiable. Every compounded medication dispensed under 503A requires a patient-specific prescription from a licensed provider. Clinical intake and prescribing workflows must be built around this requirement.
Pharmacy sourcing matters. Not all 503A pharmacies operate at the same standard. Third-party testing for potency, sterility, and quality should be a baseline requirement, not an afterthought.
State compliance applies on top of federal. State pharmacy board requirements vary. Organizations operating across multiple states should verify that their pharmacy partners are appropriately licensed in each relevant state.
Compounded medications are not FDA-approved. Patient education and informed consent must reflect this clearly.
OpenLoop works with state-licensed 503A compounding pharmacies that conduct rigorous third-party testing and only source their ingredients from FDA-registered manufacturers. Your clinical programs get a compliant foundation built in from day one.
Contact our team to learn more about how OpenLoop supports compliant medication programs.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.